达尔皮西克利布加上芳酶抑制剂与ER阳性,HER2阴性乳腺癌的新辅助化疗相比
Haoqi Wang1,2, Guoyu Zhang3, Wei Gao1
1Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Frontiers in oncology
|May 15, 2025
概括
达尔皮西克利布加上芳酶抑制剂对激素受体阳性乳腺癌的新辅助化疗具有类似的疗效,但具有更好的安全性. 这种组合疗法显示出作为替代治疗选择的希望.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 激素受体阳性 (HR+),人体表皮生长因子受体2 (HER2) 阴性乳腺癌 (BC) 治疗.
- 循环素依赖性激酶4和6抑制剂 (CDK4/6i) 与内分泌疗法 (ET) 相结合,作为新辅助化疗 (NCT) 的替代品.
研究的目的:
- 为了回顾评估dalpiciclib加上芳酶抑制剂 (AI) 的疗效和安全性,与HR+ HER2-负BC.患者的NCT相比.
主要方法:
- 单中心回顾性研究.
- 收集了HR+ HER2-阴性BC患者的临床病理学数据和治疗细节,这些患者接受了新辅助内分泌疗法 (NET) 或NCT.
- 主要终点:残留癌症负担 (RCB). 二级终点:乳腺病理完整反应 (bpCR),客观反应率 (ORR),增殖标志物和安全概况.
- 倾向性得分匹配 (PSM) 用于分析.
主要成果:
- 达尔皮西克利布加AI (NET组) 的临床反应率 (ORR) 和乳腺保护手术 (BCS) 率与NCT相比较.
- 两组都显著减少了Ki-67,在NET组中更普遍的减少为≤10%.
- 与NCT组相比,NET组的3-4级毒性发生率明显较低.
- 在PSM之后,dalpiciclib加AI显示出比NCT更安全的优势.
结论:
- 与NCT相比,dalpiciclib加AI组合疗法在HR+ HER2阴性乳腺癌中提供了可比的疗效和更好的安全性.
- 剩余癌症负担 (RCB) 和病理完整反应 (pCR) 可能不是评估基于CDK4/6i的新辅助内分泌疗法 (NET) 的最佳终点.
相关概念视频
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


